RM
Rajeev M. Shah
DELAYED 1 MONTH
10% Owner; Director; Director, 10% Owner
Acrivon Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Artiva Biotherapeutics, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Hemab Therapeutics Holdings, Inc.
Inhibikase Therapeutics, Inc.
Nkarta, Inc.
Filings
19
Companies
11
Latest
Jul 29, 2026
Transactions
Signal
Ticker / Company
Insider
Transaction
Value
Filed
—
Hemab Therapeutics Holdings, Inc.
Rajeev M. Shah
10% Owner
Purchase
$37.0K
1,483 sh
May 11 9:44 PM
May 8, 2026
—
Hemab Therapeutics Holdings, Inc.
Rajeev M. Shah
10% Owner
Purchase
$242.3K
9,906 sh
May 11 9:44 PM
May 7, 2026
—
Hemab Therapeutics Holdings, Inc.
Rajeev M. Shah
Director, 10% Owner
Purchase
$1.7M
68,018 sh
May 6 11:16 PM
May 6, 2026
—
Hemab Therapeutics Holdings, Inc.
Rajeev M. Shah
Director, 10% Owner
Purchase
$2.4M
97,411 sh
May 6 11:16 PM
May 5, 2026
—
Hemab Therapeutics Holdings, Inc.
Rajeev M. Shah
Director, 10% Owner
Purchase
$48.1M
2,675,000 sh
May 6 11:16 PM
May 4, 2026